LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
04/08/2026
Voltar para busca
Dado oficial do USPTO
V VALNEVA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
47
Atualização mais recente
04/08/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 42
Data de depósito
16/07/2014
Data de registro
21/07/2015
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
12/08/2025
Última transação
04/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
Saint Herblain, FR
Examinador
HOLTZ, ALLISON
Localização atual
Historical data usage
Descrição da marca
The mark consists of a stylized "V" consisting of three diagonal lines, first light blue, then blue, then light blue, and the word "VALNEVA" in stylized form in dark blue.
Titulares e representantes
Titulares
VALNEVA
VALNEVA
Representantes
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical productsfungicidesherbicidesinsecticides and parasiticides for use in industryscience as well as in agriculture; molecules from bio technologiesproteins in raw material for scientific and medical research; cells for scientificlaboratory or medical research; cell lines for scientific and medical research; nucleic acids for laboratory use; proteins for industrial use; recombinant proteins for industrial use; biomedical compoundspeptides substrates; peptide antigens used in analyzing and detecting certain toxins for researchclinicalmedical laboratory use; Biochemical preparations derived from blood serum for use in scientific and medical research; Bio chemicalsantibodies and fragments thereof for in vitro scientific or research useChemicals for use in biotechnological product development; cultures of microorganisms other than for medical and veterinary use; virusescellsbiologicalbacteriological or viral preparationsother than for nucleic acids for scientificlaboratorymedical research
Classe 5
Pharmaceutical products for human and veterinary use for the treatment of auto immune diseasesinflammationcancerinfectious diseasesdiseases of the central nervous systemcardiovascular diseasesneurodegenerative and chronic diseases; medicalbiologicalbiotechnologicalproteinvirologicalimmunologicalbacteriologicalchemicalenzymatic and pharmaceutical preparations for medical and veterinary use; medicalbiologicalbiotechnologicalproteinvirologicalimmunologicalbacteriologicalchemicalenzymatic and pharmaceutical productspreparation of encapsulated cells which release antibodies for medical and veterinary use; diagnostic productsdiagnostic preparations for use in humanveterinary medicine and pharmaceutical use; cellmicroorganism or virus cultures for medical and veterinary use; adjuvants for medical or veterinary use; antibioticsvaccinesvirusesviral vectorsnucleic acidsproteinsrecombinant proteinspeptidespeptide antigensblood serumantibodies and fragments thereofcells for medicalpharmaceutical and veterinary use; viral substancesimmunological substancesbacterial substancesenzyme substances used for human and veterinary medicine; diagnostic kits consisting primarily of antibodies and fragments thereof for use in disease testing; diagnostic kits primarily of antibodies and antibody fragments for use in disease testing
Classe 42
Scientific research services for medical purposes in the fields of auto immune diseasesinflammationcancerinfectious diseasesdiseasesdiseases of the central nervous systemcardiovascular diseasesneurodegenerative and chronic diseases; scientific research for medicalpharmaceutical and veterinary purposes in the fields of auto immune diseasesinflammationcancerinfectious diseasesdiseases of the central nervous systemscardiovascular diseasesneurodegenerative and chronic diseases; scientific and industrial researchin particular in the fields of biologycellular and molecular biologybiotechnologybacteriologyimmunologygeneticsgene studymedicinepharmacologyvirologychemistry; scientific research relating to vaccinesantibiotics and immunological products for human and veterinary use; research and development of new products for others; testing and evaluations of the goods of others to assure compliance with industry standards in the scientificmedical and veterinary fields; research and development of new products for human and veterinary use; scientific researchpreparation of scientific experts opinion reports in the scientificmedical and veterinary fields; development and design of laboratory instruments for scientific and industrial researchin particular to obtain and prepare cellscell linesvirusesproteinsanimal and human materials; development of vaccinesantibiotics and immunological products for human and veterinary use; scientific and technological servicesdiagnostic and prognostic analyses in the fields of cellscell linesanimal and human materialsmicroorganismsmolecules for scientific purposes; scientific researchpreparation of scientific expert opinions reports
Publicações
Histórico de despachos e eventos da marca no USPTO.
47 publicações encontradas
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
09/07/2026
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
12/08/2025
71AG
REGISTERED-SEC.71 ACCEPTED
12/08/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
29/07/2025
ES71
TEAS SECTION 71 RECEIVED
12/05/2025
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
21/07/2024
RNWL
INTERNATIONAL REGISTRATION RENEWED
07/06/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
15/10/2022
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
24/08/2021
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
24/08/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
24/08/2021
ES75
TEAS SECTION 71 & 15 RECEIVED
13/04/2021
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
21/07/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
26/09/2019
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
13/12/2018
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
22/12/2016
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/01/2016
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/12/2015
FIMP
FINAL DISPOSITION PROCESSED
09/12/2015
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
21/10/2015
R.PR
REGISTERED-PRINCIPAL REGISTER
21/07/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/05/2015
PUBO
PUBLISHED FOR OPPOSITION
05/05/2015
GPNX
NOTIFICATION PROCESSED BY IB
02/05/2015
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
15/04/2015
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
15/04/2015
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/04/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
31/03/2015
ALIE
ASSIGNED TO LIE
30/03/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/03/2015
XAEC
EXAMINER'S AMENDMENT ENTERED
12/03/2015
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/03/2015
GNEA
EXAMINERS AMENDMENT E-MAILED
12/03/2015
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/03/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/02/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/02/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/02/2015
RFNT
REFUSAL PROCESSED BY IB
04/01/2015
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
15/12/2014
RFRR
REFUSAL PROCESSED BY MPU
15/12/2014
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/12/2014
MAFR
APPLICATION FILING RECEIPT MAILED
12/12/2014
CNRT
NON-FINAL ACTION WRITTEN
11/12/2014
DOCK
ASSIGNED TO EXAMINER
08/12/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/12/2014
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/12/2014
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace V VALNEVA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.